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Breast cancer (BrC)-derived factors inhibit proper devel-
opment and activation of dendritic cells (DC), which in
turn promote the expansion of regulatory T cells
(Tregs), thus contributing to tumor progression and
spread. In two separate BrC sentinel lymph node (SLN)
cohorts, one from the EACRI in Portland and one from
the VUmc in Amsterdam, we found metastasis-related
immune suppression of CD11c+CD14-lymph node-resi-
dent conventional DC (LNR-cDC).
Genome-wide microarray analyses on FACS sorted
migratory CD1a+ cDC, LNR-cDC and CD14+ LNR-cDC
isolated from breast-draining LN were performed. A
focused analysis of c-type lectin receptors (CLR) and
transcription factor genes associated with Ag uptake and
cross-presentation, showed LNR-cDC to express relatively
high transcript levels of Interferon-regulatory factor
8 (IRF8), chemokine receptor 1 (XCR1), BDCA3/
thrombomodulin, and, remarkably, of Langerin, CLEC7A
and CLEC4A. These are interesting observations, since
these are all factors previously linked to efficient antigen
cross-presentation and cross-priming of CD8+ T cells.
The EACRI cohort (n=38) included LN from ductal
carcinoma in situ (DCIS), tumor-negative SLN (SLN-)
and metastasis-positive SLN (SLN+), analyzed with a
12-parameter flow cytometry panel. The VUmc cohort
included healthy, prophylactically removed breast LN
(HLN, n=16), SLN- and SLN+ (n=40). In both cohorts,
there was significantly reduced activation of LNR-cDC,
but not of migratory cDC, in SLN-versus DCIS/HLN
with further reductions in SLN+. Notably, reduction in
activation of LNR-cDC went hand-in-hand with
increased Treg frequencies.
We next explored the possibility to counteract this
BrC-related suppression in SLN ex vivo. The combined
activity of CpG-B and the JAK2/STAT3 inhibitor
(STAT3i) AG490 resulted in increased activation of
LNR-plasmacytoid DC and LNR-cDC. It also promoted
production of IFNg by CD8+ T cells, reduced production
of IL-4 by CD4+ T cells, and decreased rates of suppres-
sive Tregs, which were slightly elevated by CpG-B alone.
Finally, the combination of CpG-B and STAT3i
increased tumor-specific effector T cell responses as
measured by IFNg ELISPOT assay after in vitro restimu-
lation against a pool of overlapping 15-mer peptides,
covering the sequence of the BrC–associated antigen
Mammaglobin-A.
Combined, our data show that BrC-mediated suppres-
sion in SLN is primarily directed against the LNR-cDC
subset (with particular cross-presenting characteristics and
abilities), rather than CD1a+ cDC subsets that migrate to
the SLN from local tissues. Stimulation with CpG-B and
STAT3i could reactivate these suppressed LNR-cDC ex
vivo, thereby restoring type-1 mediated anti-tumor immu-
nity. In view of increasing evidence that immune-regulated
pathways influence response to (neo)adjuvant chemother-
apy, we anticipate clinical benefit of combination therapy
with this immune-stimulatory cocktail.
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